<code id='9981C0EB34'></code><style id='9981C0EB34'></style>
    • <acronym id='9981C0EB34'></acronym>
      <center id='9981C0EB34'><center id='9981C0EB34'><tfoot id='9981C0EB34'></tfoot></center><abbr id='9981C0EB34'><dir id='9981C0EB34'><tfoot id='9981C0EB34'></tfoot><noframes id='9981C0EB34'>

    • <optgroup id='9981C0EB34'><strike id='9981C0EB34'><sup id='9981C0EB34'></sup></strike><code id='9981C0EB34'></code></optgroup>
        1. <b id='9981C0EB34'><label id='9981C0EB34'><select id='9981C0EB34'><dt id='9981C0EB34'><span id='9981C0EB34'></span></dt></select></label></b><u id='9981C0EB34'></u>
          <i id='9981C0EB34'><strike id='9981C0EB34'><tt id='9981C0EB34'><pre id='9981C0EB34'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:3211
          A scientist working at SQZ Biotechnologies in Watertown's Arsenal Yards. -- biotech coverage from STAT
          A scientist working at SQZ Biotechnologies in Watertown, Mass. David L Ryan/Globe Staff

          Next stop: Beacon Hill.

          Governor Maura Healey’s long-awaited plan to double down on state funding for the biotech and medical technology sector came into focus Thursday with the announcement she’ll seek $1 billion over the next decade to reauthorize the state’s 16-year-old life sciences initiative.

          advertisement

          But lawmakers so far are noncommittal on funding the plan. The proposal — dubbed “Life Sciences 3.0″ — is part of a larger economic development bill the Healey administration is expected to file soon. Several expressed support for an industry in which Massachusetts is a leader, but also noted the spending request comes at a time of competing priorities.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          FDA early review: GLP
          FDA early review: GLP

          SarahSilbiger/GettyImagesApreliminaryevaluationbytheFoodandDrugAdministrationdidnotfindevidencethatG

          read more
          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more

          What don’t we know about an Alzheimer’s drug side effect?

          Illustration:AlexHogan/STAT;Photo:EisaiviaAPSincetheFDA’sapprovaloflecanemab(marketedasLeqembi)andMe